- Previous Rank
- Revenue 3 Yr Annual Growth Rate46
- Revenue 3 Yr Growth Rank19
- EPS 3 Yr Annual Growth Rate154
- EPS 3 Yr Growth Rank5
- Total Return 3 Yr Annual Rate52
- Total Return 3 Yr Rank8
Supernus Pharmaceuticals is tackling what is, perhaps, the most difficult project in the life sciences sector—treating the diseases that afflict our brains, including epilepsy and migraines. In the second quarter of 2018, the firm’s revenues ballooned by more than 30% to $99.5 million, driven by greater sales of flagship drugs Oxtellar XR and Trokendi XR. The company’s latest earnings figures fell a bit short of Wall Street expectations, but that may not be of much concern given how hot the stock has been over the past five years: It has provided shareholders with a stunning 571% return.
Company Information
| Location | Rockville, Md. |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Current Streak | - |
| Years on List | 1 |
| CEO | Jack Khattar |
| Website | www.supernus.com |
Revenue, Net Income
| Revenue past four quarters ($M) | $335 |
| Net Income past four quarters ($M) | $73 |
Growth Rates and Ranks
| Revenue 3 Yr Growth Rank | 19 |
| Revenue 3 Yr Annual Growth Rate | 46% |
| EPS 3 Yr Growth Rank | 5 |
| EPS 3 Yr Annual Growth Rate | 154% |
| Total Return 3 Yr Rank | 8 |
| Total Return 3 Yr Annual Rate | 52% |
| Beat S&P 500 (11.9%) | yes |
| P/E Ratio | 29 |